Design, Synthesis,  In-Silico  Study of Novel Benzofuran Thiazolyl Hydrazones as Anticancer Agents Targeting EGFR Kinase

Sonali Sandeep Shinde; Jaydeo Tirthraj Kilbile; Sachin Shivling Bhusari; Pravin Shridhar Wakte

doi:10.22146/ijc.106097

Design, Synthesis, In-Silico Study of Novel Benzofuran Thiazolyl Hydrazones as Anticancer Agents Targeting EGFR Kinase

https://doi.org/10.22146/ijc.106097

Sonali Sandeep Shinde⁽¹⁾, Jaydeo Tirthraj Kilbile⁽²⁾, Sachin Shivling Bhusari⁽³⁾, Pravin Shridhar Wakte^(4*)

(1) Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, 431004 Maharashtra, India
(2) Department of Chemistry, School of Basic and Applied Sciences, MGM University, Chhatrapati Sambhajinagar, 431003 Maharashtra, India
(3) Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, 431004 Maharashtra, India
(4) Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, 431004 Maharashtra, India
(*) Corresponding Author

Abstract

In the current investigation, a series of new benzofuran-thiazolyl hydrazones 5(a–h) were synthesized, characterized, and tested for anticancer activity against selected cancer cell lines, including A549, MCF-7, and DU-145, using MTT and EGFR enzymatic assays. The synthesized compounds 5g and 5h showed considerable anticancer activity, with IC₅₀ values ranging from 9.05 to 18.09 μM and 12.03 to 13.09 μM, respectively. Doxorubicin and osimertinib were used as the standard drugs for comparison of activity. Compounds 5g and 5h also showed significant antioxidant activity as measured by the DPPH method. The molecular docking investigation was conducted against the EGFR (PDB: 1M17) to learn about the interactions of synthesized compounds with binding pockets. Furthermore, an ADME research and molecular dynamics simulation study was conducted to provide insight into drug-likeness and conformational stability. The results show a good match between reported anticancer effects and computational analyses. Compounds 5g and 5h exhibited significant cytotoxicity against lung, breast, and prostate cancer cell lines. These findings underscore the potential of benzofuran-thiazolyl hydrazone derivatives as promising candidates for the development of novel anticancer therapeutics.

Keywords

benzofuran; thiazole; hydrazone; anticancer; EGFR; molecular docking; enzymatic assay

Full Text:

Full Text PDF Full Text PDF-Suppl. Data

References

[1] Siegel, R.L., Kratzer, T.B., Giaquinto, A.N., Sung, H., and Jemal, A., 2025, Cancer statistics, Ca-Cancer J. Clin., 75 (1), 10–45.

[2] Wee, P., and Wang, Z., 2017, Epidermal growth factor receptor cell proliferation signaling pathways, Cancers, 9 (5), 52.

[3] Yu, H., 2023, Optimising Cancer Therapeutics: An In Vitro and In Silico Approach, Dissertation, Aston University, UK.

[4] Mejía-Caballero, A., Salas-Villagrán, V.A., Jiménez-Serna, A., and Farrés, A., 2021, Challenges in the production and use of probiotics as therapeutics in cancer treatment or prevention, J. Ind. Microbiol. Biotechnol., 48 (9-10), kuab052.

[5] Yaron-Barir, T.M., Joughin, B.A., Huntsman, E.M., Kerelsky, A., Cizin, D.M., Cohen, B.M., Regev, A., Song, J., Vasan, N., Lin, T.Y., Orozco, J.M., Schoenherr, C., Sagum, C., Bedford, M.T., Wynn, R.M., Tso, S.C., Chuang, D.T., Li, L., Li, S.S.C., Creixell, P., Krismer, K., Takegami, M., Lee, H., Zhang, B., Lu, J., Cossentino, I., Landry, S.D., Uduman, M., Blenis, J., Elemento, O., Frame, M.C., Hornbeck, P.V., Cantley, L.C., Turk, B.E., Yaffe, M.B., and Johnson, J.L., 2024, The intrinsic substrate specificity of the human tyrosine kinome, Nature, 629 (8014), 1174–1181.

[6] Raghu, M.S., Swarup, H.A., Shamala, T., Prathibha, B.S., Kumar, K.Y., Alharethy, F., Prashanth, M.K., and Jeon, B.H., 2023, Design, synthesis, anticancer activity, and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors, Heliyon, 9 (9), e20300.

[7] Wang, S., Song, Y., and Liu, D., 2017, EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance, Cancer Lett., 385, 51–54.

[8] Milik, S.N., Lasheen, D.S., Serya, R.A., and Abouzid, K.A., 2017, How to train your inhibitor: Design strategies to overcome resistance to epidermal growth factor receptor inhibitors, Eur. J. Med. Chem., 142, 131–151.

[9] Das, D., and Hong, J., 2019, Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry, Eur. J. Med. Chem., 170, 55–72.

[10] El-Sherief, H.A.M., Youssif, B.G.M., Abdelazeem, A.H., Abdel-Aziz, M., and Abdel-Rahman, H.M., 2019, Design, synthesis and antiproliferative evaluation of novel 1,2,4-triazole/Schiff base hybrids with EGFR and B-RAF inhibitory activities, Anti-Cancer Agents Med. Chem., 19 (5), 697–706.

[11] Hashem, H.E., Amr, A.E.G.E., Nossier, E.S., Anwar, M.M., and Azmy, E.M., 2022, New benzimidazole-, 1,2,4-triazole-, and 1,3,5-triazine-based derivatives as potential EGFRWT and EGFRT790M inhibitors: Microwave-assisted synthesis, anticancer evaluation, and molecular docking study, ACS Omega, 7 (8), 7155–7171.

[12] Kardile, R.A., Sarkate, A.P., Lokwani, D.K., Tiwari, S.V., Azad, R., and Thopate, S.R., 2023, Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions, Eur. J. Med. Chem., 245, 114889.

[13] Karnik, K.S., Sarkate, A.P., Tiwari, S.V., Azad, R., and Wakte, P.S., 2021, Free energy perturbation guided synthesis with biological evaluation of substituted quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC), Bioorg. Chem., 115, 105226.

[14] Jiao, X., Zhang, Q., Zhang, Y., Shao, J., Ding, L., Tang, C., and Feng, B., 2022, Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR/HER2 dual-target inhibitors, Bioorg. Med. Chem. Lett., 67, 128703.

[15] Ibrahim, M.T., Uzairu, A., Uba, S., and Shallangwa, G.A., 2021, Design of more potent quinazoline derivatives as EGFR WT inhibitors for the treatment of NSCLC: A computational approach, Future J. Pharm. Sci., 7 (1), 140.

[16] Ahmed, N.M., Youns, M.M., Soltan, M.K., and Said, A.M., 2021, Design, synthesis, molecular modeling and antitumor evaluation of novel indolyl-pyrimidine derivatives with EGFR inhibitory activity, Molecules, 26 (7), 1838.

[17] Al-Anazi, M., Khairuddean, M., Al-Najjar, B.O., Alidmat, M.M., Nik Mohamed Kamal, N.N.S., and Muhamad, M., 2022, Synthesis, anticancer activity and docking studies of pyrazoline and pyrimidine derivatives as potential epidermal growth factor receptor (EGFR) inhibitors, Arabian J. Chem., 15 (7), 103864.

[18] Farghaly, T.A., Abbas, E.M., Al-Soliemy, A.M., Sabour, R., and Shaaban, M.R., 2022, Novel sulfonyl thiazolyl-hydrazone derivatives as EGFR inhibitors: Design, synthesis, biological evaluation and molecular docking studies, Bioorg. Chem., 121, 105684.

[19] Al-Wahaibi, L.H., El-Sheref, E.M., Hassan, A.A., Bräse, S., Nieger, M., Youssif, B.G.M., Ibrahim, M.A., and Tawfeek, H.N., 2023, Synthesis and structure determination of substituted thiazole derivatives as EGFR/BRAFV600E dual inhibitors endowed with antiproliferative activity, Pharmaceuticals, 16 (7), 1014.

[20] Xu, Z., Xu, D., Zhou, W., and Zhang, X., 2022, Therapeutic potential of naturally occurring benzofuran derivatives and hybrids of benzofurans with other pharmacophores as antibacterial agents, Curr. Top. Med. Chem., 22 (1), 64–82.

[21] Scibetta, S., Miceli, M., Iuliano, M., Stefanuto, L., Carbone, E., Piscopo, P., Petrozza, V., Romeo, G., Mangino, G., Calogero, A., Gasperi, T., and Rosa, P., 2024, In vitro evaluation of the antioxidant capacity of 3,3-disubstituted-3H-benzofuran-2-one derivatives in a cellular model of neurodegeneration, Life, 14 (4), 422.

[22] El-Khouly, O.A., Henen, M.A., El-Sayed, M.A.A., Shabaan, M.I., and El-Messery, S.M., 2021, Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study, Bioorg. Med. Chem., 31, 115976.

[23] Bendi, A., Sirija, M.R., Bhathiwal, A.S., Chinmay, C., Chauhan, V., and Tiwari, A., 2024, Exploring the potential therapeutic role of benzofuran derivatives in cancer treatment, J. Mol. Struct., 1317, 139121.

[24] Mphahlele, M.J., Maluleka, M.M., Parbhoo, N., and Malindisa, S.T., 2018, Synthesis, evaluation for cytotoxicity and molecular docking studies of benzo[c]furan-chalcones for potential to inhibit tubulin polymerization and/or EGFR-tyrosine kinase phosphorylation, Int. J. Mol. Sci., 19 (9), 2552.

[25] Petrou, A., Fesatidou, M., and Geronikaki, A., 2021, Thiazole ring—A biologically active scaffold, Molecules, 26 (11), 3166.

[26] Sanachai, K., Aiebchun, T., Mahalapbutr, P., Seetaha, S., Tabtimmai, L., Maitarad, P., Xenikakis, I., Geronikaki, A., Choowongkomon, K., and Rungrotmongkol, T., 2021, Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives, RSC Med. Chem., 12 (3), 430–438.

[27] Al-Salmi, F.A., Alrohaimi, A.H., El Behery, M., Megahed, W., Abu Ali, O.A., Elsaid, F.G., Fayad, E., Mohammed, F.Z., and Keshta, A.T., 2023, Anticancer studies of newly synthesized thiazole derivatives: Synthesis, characterization, biological activity, and molecular docking, Crystals, 13 (11), 1546.

[28] Verma, G., Marella, A., Shaquiquzzaman, M., Akhtar, M., Ali, M.R., and Alam, M.M., 2024, A review exploring biological activities of hydrazones, J. Pharm. BioAllied Sci., 6, 69–80.

[29] Al-Hazmi, G.H., 2023, In vitro biological evaluation of some synthesized novel 5-substituted-2-(substituted)hydazineyl-1,3-thiazolidin-4-ones, Russ. J. Bioorg. Chem., 49 (5), 1000–1013.

[30] Rathod, S.S., Shinde, S.S., Choudhari, P.B., Dhavale, R.P., and Sarkate, A.P., 2024, “Computational and Experimental Approaches to Decipher the Complexity of Diseases” in Systems Biology Approaches: Prevention, Diagnosis, and Understanding Mechanisms of Complex Diseases, Eds. Joshi, S., Ray, R.R., Nag, M., and Lahiri, D., Springer Nature Singapore, Singapore, 393–413.

[31] Shinde, S.S., Ahmed, S., Malik, J.A., Hani, U., Khanam, A., Ashraf Bhat, F., Ahmad Mir, S., Ghazwani, M., Wahab, S., Haider, N., and Almehizia, A.A., 2023, Therapeutic delivery of tumor suppressor miRNAs for breast cancer treatment, Biology, 12 (3), 467.

[32] Rathod, S., Shinde, S., Choudhari, P., Sarkate, A., Chaudhari, S., and Shingan, A., 2025, Exploring binding potential of two new indole alkaloids from Nauclea officinalis against third and fourth generation EGFR: Druglikeness, in silico ADMET, docking, DFT, molecular dynamics simulation, and MMGBSA study, Nat. Prod. Res., 39 (10), 2970–2977.

[33] Xochicale-Santana, L., Vidyasagar, C.C., Muñoz-Flores, B.M., and Pérez, V.M.J., 2021, Microwave assisted organic syntheses (MAOS): The green synthetic method, Handb. Greener Synth. Nanomater. Compd., 1, 491–542.

[34] Shinde, S.S., Sarkate, A.P., Rathod, S.S., Kilbile, J.T., Chaudhari, S.Y., Yadala, R., Pawar, S.C., and Wakte, P.S., 2024, Synthesis, biological evaluation, and computational studies of thiazolyl hydrazone derivatives as triple mutant allosteric EGFR inhibitors, J. Chin. Chem. Soc., 71 (7), 706–720.

[35] Pawar, C.D., Chavan, S.L., Pawar, U.D., Pansare, D.N., Deshmukh, S.V., and Shinde, D.B., 2019, Synthesis, anti-proliferative activity, SAR, and kinase inhibition studies of thiazol-2-yl-substituted sulfonamide derivatives, J. Chin. Chem. Soc., 66 (3), 257–264.

[36] Karnik, K.S., Sarkate, A.P., Lokwani, D.K., Tiwari, S.V., Azad, R., and Wakte, P.S., 2023, Molecular dynamic simulations based discovery and development of thiazolidin-4-one derivatives as EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC), J. Biomol. Struct. Dyn., 41 (10), 4696–4710.

[37] Shinde, S.S., Padule, K.B., Sawant, S.L., and Sarkate, A.P., 2024, “Systems Approach for Identifying Drug Targets by Computational Approaches” in Systems Biology Approaches: Prevention, Diagnosis, and Understanding Mechanisms of Complex Diseases, Eds. Joshi, S., Ray, R.R., Nag, M., and Lahiri, D., Springer Nature Singapore, Singapore, 257–270.

[38] Shinde, S.S., Giram, P.S., Wakte, P.S., and Bhusari, S.S., 2025, ADMET tools in the digital era: Applications and limitations, Adv. Pharmacol., 103, 65–80.

[39] Tivari, S.R., Kokate, S.V., Belmonte-Vázquez, J.L., Pawar, T.J., Patel, H., Ahmad, I., Gayke, M.S., Bhosale, R.S., Jain, V.D., Muteeb, G., Delgado-Alvarado, E., and Jadeja, Y., 2023, Synthesis and evaluation of biological activities for a novel 1,2,3,4-tetrahydroisoquinoline conjugate with dipeptide derivatives: Insights from molecular docking and molecular dynamics simulations, ACS Omega, 8 (51), 48843–48854.

[40] Shinde, S.S., Bhusari, S.S., and Wakte, P.S., 2024, Exploring the potent anticancer activity of novel phytoconstituent derived from Zanthoxylum nitidum using an in-silico approach, Curr. Pharmacogenomics Pers. Med., 22, 104–115.

[41] Abdalla, M., Eltayb, W.A., El-Arabey, A.A., Singh, K., and Jiang, X., 2022, Molecular dynamic study of SARS-CoV-2 with various S protein mutations and their effect on thermodynamic properties, Comput. Biol. Med., 141, 105025.

[42] Siva Kumar, B., Anuragh, S., Kammala, A.K., and Ilango, K., 2022, Computer aided drug design approach to screen phytoconstituents of Adhatoda vasica as potential inhibitors of SARS-CoV-2 main protease enzyme, Life, 12 (2), 315.

[43] Prakash, P., Gayathiri, E., Rahaman, M., Periyasami, G., Pandiaraj, S., Pratheep, T., Selvam, K., Chaudhari, S.Y., Thirumalaivasan, N., Thomas, J., Hatami, M., Govindasamy, R., and Thiruvengadam, M., 2023, Exploring the potential of targeting insulin-like growth factor-1 through network pharmacology, molecular docking, molecular dynamics, and experimental validation of antioxidant and anti-inflammatory activities, S. Afr. J. Bot., 162, 707–718.

[44] Bhandari, S.V., Kuthe, P.V., Patil, S.M., Nagras, O.G., Sarkate, A.P., Chaudhari, S.Y., and Surve, S.V., 2023, Molecular docking, pharmacokinetic and molecular simulation analysis of novel mono‐carbonyl curcumin analogs as L858R/T790M/C797S mutant EGFR inhibitors, Chem. Biodivers., 20 (11), e202301081.

[45] Mohankumar, T., Chandramohan, V., Laliithamba, H.S., Jayaraj, R.L., Kumaradhas, P., Sivanandam, M., Hunday, G., Vijayakumar, R., Balakrishnan, R., Manimaran, D., and Elangovan, N., 2020, Design and molecular dynamic investigations of 7,8-dihydroxyflavone derivatives as potential neuroprotective agents against alpha-synuclein, Sci. Rep., 10 (1), 599.

[46] Gaikwad, N.M., Chaudhari, P.D., Shaikh, K.S., Chaudhari, S.Y., Saleem, R.M., Algahtani, M., Altyar, A.E., Albadrani, G.M., Kamel, M., and Abdel-Daim, M.M., 2023, Albendazole repurposing on VEGFR-2 for possible anticancer application: In-silico analysis, PLoS One, 18 (8), e0287198.

[47] Zaki, M.E.A., Al-Hussain, S.A., Al-Mutairi, A.A., Samad, A., Ghosh, A., Chaudhari, S., Khatale, P.N., Jawarkar, R.D., and Jawarkar, R.D., 2023, In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as potential onco-immunomodulators, Front. Pharmacol., 14, 1129997.

[48] Lee, Y., Lee, S., Lee, Y., Song, D., Park, S.H., Kim, J., Namkung, W., and Kim, I., 2024, Anticancer evaluation of novel benzofuran–indole hybrids as epidermal growth factor receptor inhibitors against non-small-cell lung cancer cells, Pharmaceuticals, 17 (2), 231.

[49] Mirgany, T.O., Motiur Rahman, A.F.M., and Alanazi, M.M., 2024, Design, synthesis, and mechanistic evaluation of novel benzimidazole-hydrazone compounds as dual inhibitors of EGFR and HER2: Promising candidates for anticancer therapy, J. Mol. Struct., 1309, 138177.

[50] Yamauchi, M., Kitamura, Y., Nagano, H., Kawatsu, J., and Gotoh, H., 2024, DPPH measurements and structure–activity relationship studies on the antioxidant capacity of phenols, Antioxidants, 13 (3), 309.

[51] Jaber, Q.A.H., Shentaif, A.H., Almajidi, M., Ahmad, I., Patel, H., Azad, A.K., Alnasser, S.M., Alatawi, H.A., Menaa, F., Alfaifi, S.Y., Rahman, M.M., Ali, M.M., and Rao, S.J.A., 2023, Synthesis, structure, and in vitro pharmacological evaluation of some new pyrimidine-2-sulfonamide derivatives and their molecular docking studies on human estrogen receptor alpha and CDK2/cyclin proteins, Russ. J. Bioorg. Chem., 49 (1), S106–S118.

DOI: https://doi.org/10.22146/ijc.106097